However, overexpression of MXD3 was associated with shorter survival of prostate adenocarcinoma (PRAD), mesothelioma (MESO), LGG, KICH, uveal melanoma (UVM), lung adenocarcinoma (LUAD), KIRC, ACC, THYM, HNSC, LICH, and glioblastoma multiforme (GBM) (Fig. 3D). Here, MXD3 is linked to prostate adenocarcinoma.